Compare Toronto-Dominion Bank (TD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toronto-Dominion Bank vs TG Therapeutics Inc — how do they compare? Toronto-Dominion Bank trades at $115.13 (market cap $185.79B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: Toronto-Dominion Bank is far larger — about 22.8× TG Therapeutics Inc's market cap, and Toronto-Dominion Bank pays a 2.84% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Toronto-Dominion Bank for 84 Days and TG Therapeutics Inc for 16 Days on average.
| TD | TGTX | |
|---|---|---|
Market Cap | $185.79B | $8.16B |
Volume | 3,263,867 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $124.80 | $59.06 |
52-Week Low | $78.32 | $26.94 |
Typical Hold Time | 84 Days | 16 Days |
Enterprise Value | $559.06B | $8.37B |
Dividend Yield | 2.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TD Bank trades at $114.39, up 0.46% with bearish technical signals despite strong earnings beats. The stock shows robust fundamentals with 24.88% net margin and 13.64% ROE, supported by a $10 billion buyback program announced September 2026. Revenue growth accelerated to $61.28 billion in 2025 with profit margins recovering to 33.51%. Analyst consensus leans bullish with 9 buy ratings versus 8 holds and no sell recommendations.
TD presents a compelling value opportunity with reasonable P/E of 17.36 and consistent earnings outperformance. Key risks include declining operating cash flow trends and elevated debt-to-asset ratio of 20.86%. The bank's $108 billion Canadian infrastructure commitment and U.S. branch expansion provide growth catalysts, though technical indicators suggest near-term pressure.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
